argenx (ARGX) Q3 2024 earnings summary

Executive summary

• Achieved 11th consecutive quarter of growth, with $573 million in Q3 2024 product net sales, a 74% year-over-year and 20% sequential increase, driven by VYVGART expansion in gMG, CIDP, and ITP.

• Over 300 CIDP patients on therapy at quarter-end, with robust U.S. launch and early ITP success in Japan.

• Vision 2030 targets 50,000 patients globally, 10 labeled indications, and five new Phase 3 molecules by 2030.

• Discontinued efgartigimod in membranous nephropathy due to insufficient efficacy, with focus on high-impact programs.

• Ended Q3 2024 with $3.4 billion in cash, supporting ongoing R&D and commercial activities.

Financial highlights

• Q3 2024 total operating income was $589 million, including $573 million in product net sales and $16 million in other income.

• U.S. product sales were $492 million, with $24 million from Japan, $46 million from rest of world, and $11 million from Zai Lab in China.

• Operating expenses reached $575 million, up $40 million sequentially, driven by SG&A, R&D, and cost of sales increases.

• Q3 operating profit was $14 million; net profit after tax was $91 million for the quarter and $59 million year-to-date.

• Cash, cash equivalents, and current financial assets totaled $3.4 billion as of September 30, 2024.

Outlook and guidance

• Combined SG&A and R&D expenses guidance remains at approximately $2 billion.

• Regulatory reviews for CIDP ongoing in China, Japan, Europe, and planned in Canada; approval decisions expected in 2025.

• Prefilled syringe (PFS) PDUFA date set for April 2025; ex-US filings ongoing.

• Five registrational trials expected by year-end 2024, with multiple pipeline milestones and a detailed 2025 clinical calendar to be announced.

• No revenue or patient number guidance for CIDP; launch KPIs to be provided.